4.4 Review

ITK Inhibitors in Inflammation and Immune-Mediated Disorders

Journal

CURRENT TOPICS IN MEDICINAL CHEMISTRY
Volume 9, Issue 8, Pages 690-703

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156802609789044443

Keywords

-

Funding

  1. NIH [AI51626, AI065566, AI073955]
  2. PA Department of Health
  3. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065566, R01AI051626, R01AI073955, R56AI073955, R56AI065566] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Interleukin-2-inducible T cell kinase (ITK) is a non-receptor tyrosine kinase expressed in T cells, NKT cells and mast cells which plays a crucial role in regulating the T cell receptor (TCR), CD28, CD2, chemokine receptor CXCR4, and Fc epsilon R-mediated signaling pathways. In T cells, ITK is an important mediator for actin reorganization, activation of PLC gamma, mobilization of calcium, and activation of the NFAT transcription factor. ITK plays an important role in the secretion of IL-2, but more critically, also has a pivotal role in the secretion of Th2 cytokines, IL-4, IL-5 and IL-13. As such, ITK has been shown to regulate the development of effective Th2 response during allergic asthma as well as infections by parasitic worms. This ability of ITK to regulate Th2 responses, along with its pattern of expression, has led to the proposal that it would represent an excellent target for Th2-mediated inflammation. We discuss here the possibilities and pitfalls of targeting ITK for inflammatory disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available